Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T20:29:24.201Z Has data issue: false hasContentIssue false

Critical approach to antidepressant trials

Blindness protection is necessary, feasible and measurable

Published online by Cambridge University Press:  02 January 2018

C. Even*
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France
E. Siobud-Dorocant
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France
R. M. Dardennes
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France
*
Dr C. Even, Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France
Rights & Permissions [Opens in a new window]

Abstract

Background

Double-blind placebo-controlled trials are the academic standard for clinical psychopharmacology research.

Aims

To identify the potential defects of current double-blind procedures in trials involving antidepressants and to investigate whether safeguards for blindness protection are used.

Method

We reviewed the literature and devised a short seven-item checklist for evaluating the quality of blindness protection. We performed a computerised search for 1998 to identify the placebo-controlled studies that evaluated the efficacy of an antidepressant. The checklist was used to assess all traceable antidepressant trials published in 1998.

Results

Relevant criticisms question the blindness procedures. The available methods which may bolster blindness are very seldom used.

Conclusions

Improvement in the blindness procedures used for antidepressant trials is necessary, feasible and measurable.

Information

Type
Papers
Copyright
Copyright © 2000 The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.